Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Uterine Cervical Neoplasms 12Nasopharyngeal Carcinoma 8Head and Neck Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Squamous Cell Carcinoma of Head and Neck 5Esophageal Neoplasms 5Recurrence 4Nasopharyngeal Neoplasms 4Lung Neoplasms 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Osteosarcoma 3Neuroblastoma 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Squamous Cell 3Small Cell Lung Carcinoma 2Peritoneal Neoplasms 2Neoplasms 2Hyperthermia 2Fallopian Tube Neoplasms 2Cholangiocarcinoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vomiting 1Virus Diseases 1Tumor Virus Infections 1Tongue Neoplasms 1

Interventions

spartalizumab 1liposomal doxorubicin 1Salvia hispanica seed extract 1Rituximab 1Prednisone 1Methotrexate 1Gemcitabine 1Dexamethasone 1Clinical Protocols 1Cisplatin 1Cholecalciferol 1Azacitidine 1Asparaginase 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Lymphoma, T-Cell × Cisplatin × Clear all
NCT05821192 2023-04-20

Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.

The First Hospital of Jilin University

Phase NA Unknown
34 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡